Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine significantly reduces levels of HIV RNA and HIV DNA rebound following ART interruption in a phase I/II randomized controlled clinical trial

• Erwann P. Loret,
• Albert Darque,
• Elvenn A. Loret,
• Corinne Nicolino-Brunet,
• Sophie Morange,
• Elisabeth Castagnier,
• Josiane Casanova,
• Christine Caloustian,
• Charléric Bornet,
• Julie Coussirou,
• Jihen Bousseta,
• Bertrand Dussol,
• Isabelle Ravaux

Affiliations

Erwann P. Loret

ETRAV Laboratory CNRS/AMU, Marseille, France

Albert Darque

ETRAV Laboratory CNRS/AMU, Marseille, France; La Conception University Hospital, Dispensary, Marseille, France

Elvenn A. Loret

ETRAV Laboratory CNRS/AMU, Marseille, France

Corinne Nicolino-Brunet

ETRAV Laboratory CNRS/AMU, Marseille, France

Sophie Morange

Clinical Investigation Center, La Conception University Hospital, Marseille, France

Elisabeth Castagnier

Clinical Investigation Center, La Conception University Hospital, Marseille, France

Josiane Casanova

Clinical Investigation Center, La Conception University Hospital, Marseille, France

Christine Caloustian

Clinical Investigation Center, La Conception University Hospital, Marseille, France

Charléric Bornet

La Conception University Hospital, Dispensary, Marseille, France

Julie Coussirou

La Conception University Hospital, Dispensary, Marseille, France

Jihen Bousseta

La Conception University Hospital, Dispensary, Marseille, France

Bertrand Dussol

Clinical Investigation Center, La Conception University Hospital, Marseille, France

Isabelle Ravaux

ETRAV Laboratory CNRS/AMU, Marseille, France